Vericel (NASDAQ:VCEL) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Vericel (NASDAQ:VCEL) in a report issued on Friday morning,Benzinga reports. They currently have a $60.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Vericel’s Q4 2024 earnings at $0.37 EPS and Q3 2025 earnings at $0.09 EPS.

A number of other research analysts have also recently commented on VCEL. Truist Financial upped their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Canaccord Genuity Group started coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. Canaccord Genuity Group started coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 8th. Finally, Stephens boosted their target price on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus target price of $57.71.

Vericel Stock Performance

Shares of NASDAQ:VCEL traded up $3.97 during midday trading on Friday, hitting $54.00. 645,360 shares of the stock were exchanged, compared to its average volume of 429,835. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of 900.00 and a beta of 1.66. The business’s 50-day moving average price is $44.27 and its 200 day moving average price is $46.40. Vericel has a 12 month low of $32.28 and a 12 month high of $54.47.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The firm had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. As a group, sell-side analysts expect that Vericel will post 0.12 EPS for the current year.

Insider Transactions at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares in the company, valued at approximately $9,142,373.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $454,960. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,166 shares of company stock valued at $1,200,764 in the last quarter. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vericel

Several hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its stake in shares of Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 220 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares during the period. Swiss National Bank grew its position in Vericel by 0.4% in the 1st quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock worth $4,656,000 after purchasing an additional 400 shares during the last quarter. PFG Investments LLC boosted its holdings in shares of Vericel by 6.2% in the second quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 400 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.